- According to a Reuters report, Africa's public health body signed a memorandum of understanding with Pfizer Inc PFE, allowing African countries to access Paxlovid at cost.
- The news comes just a few months after researchers with the Drugs for Neglected Diseases Initiative reported that they were denied access to Paxlovid for use in a large study in 10 African countries that aim to find treatments for mild to moderate COVID-19.
- According to a Nature report, Pfizer denied the access because it already had plans to conduct similar trials.
- Related: FDA Authorizes Pharmacists to Prescribe Pfizer's COVID-19 Therapy.
- According to a November readout, Paxlovid reduced the risk of hospitalization or death by nearly 90% in unvaccinated adults.
- However, the benefit was less evident in patients who have already been vaccinated or are at a lower risk.
- In one subgroup analysis, Paxlovid showed a 57% reduction in hospitalizations and death for vaccinated patients with at least one risk factor for severe Covid. The difference was not statistically significant.
- Price Action: PFE shares closed at $53.42 on Thursday.
- Photo via Company
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in